Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.
You may also be interested in...
FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep
Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.
FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep
Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.
Genzyme Submits Mozobil In U.S. And Europe
Stem-cell mobilizer targets a shrinking niche market, analyst tells "The Pink Sheet" DAILY.